IRIS
TONIUTTO, Pierluigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.372
EU - Europa 3.076
AS - Asia 808
Continente sconosciuto - Info sul continente non disponibili 19
AF - Africa 9
SA - Sud America 5
OC - Oceania 2
Totale 17.291
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.285
UA - Ucraina 1.043
DE - Germania 482
CN - Cina 468
IT - Italia 361
SE - Svezia 307
FI - Finlandia 239
IE - Irlanda 235
TR - Turchia 194
FR - Francia 177
GB - Regno Unito 107
CA - Canada 86
IR - Iran 36
BE - Belgio 34
IN - India 32
RU - Federazione Russa 25
SG - Singapore 25
VN - Vietnam 21
EU - Europa 19
KR - Corea 16
PL - Polonia 13
CZ - Repubblica Ceca 9
TG - Togo 9
NL - Olanda 8
AT - Austria 6
CH - Svizzera 6
HK - Hong Kong 5
EE - Estonia 4
ES - Italia 4
BG - Bulgaria 3
CL - Cile 3
JP - Giappone 3
LI - Liechtenstein 3
PK - Pakistan 3
AU - Australia 2
BN - Brunei Darussalam 2
BR - Brasile 2
HR - Croazia 2
TW - Taiwan 2
CR - Costa Rica 1
DK - Danimarca 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
ME - Montenegro 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 17.291
Salva come PNG Salva come JPEG
Città #
Fairfield 1.862
Woodbridge 1.800
Ann Arbor 1.043
Houston 1.006
Chandler 1.002
Ashburn 841
Seattle 759
Wilmington 737
Jacksonville 704
Cambridge 637
Dearborn 463
Princeton 229
Udine 226
Dublin 222
Beijing 208
Izmir 173
San Diego 87
Ottawa 67
Boardman 65
Des Moines 49
New York 45
Norwalk 35
Brussels 34
Ogden 34
Hefei 33
Kunming 31
Falls Church 30
Nanjing 27
Leawood 25
Los Angeles 24
Dong Ket 21
Singapore 18
San Mateo 17
Zanjan 16
Guangzhou 15
Jinan 15
Warsaw 13
Washington 13
Augusta 12
Grafing 11
Hebei 11
Nanchang 11
Trieste 11
Toronto 10
Ardabil 9
Chongqing 9
Fuzhou 9
Hangzhou 9
Lomé 9
Andover 8
Monmouth Junction 8
Phoenix 8
Seongnam 8
Zhengzhou 8
Brno 7
Chengdu 7
Helsinki 7
Indiana 7
London 6
Mumbai 6
Ningbo 6
Shanghai 6
Shenyang 6
Vienna 6
Wuhan 6
Edinburgh 5
Milan 5
Redmond 5
San Francisco 5
San Jose 5
Zurich 5
Auburn Hills 4
Changsha 4
Henderson 4
Hong Kong 4
Hyderabad 4
Maserada Sul Piave 4
Monza 4
Stockholm 4
Tallinn 4
Verona 4
Frankfurt am Main 3
Gatchina 3
Jinhua 3
Piacenza 3
Pune 3
Quzhou 3
Redwood City 3
Rome 3
Schaan 3
Seoul 3
Sofia 3
Tokyo 3
Villafranca in Lunigiana 3
Wenzhou 3
Xian 3
Yellow Springs 3
Acworth 2
Agugliano 2
Ahmedabad 2
Totale 12.971
Salva come PNG Salva come JPEG
Nome #
Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. 177
Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF). 176
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 170
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 162
Steatosis of the graft is a risk factor for posttransplantation biliary complications. 159
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 153
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 151
Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. 149
Management of infections in cirrhotic patients: report of a consensus conference. 149
The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 148
Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. 142
A single-center experience of late retransplantation of the liver. 142
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis 141
Toll Like Receptor 4 D299G Associates with Disease Progression in Caucasian Patients with Chronic HBV Infection: Relationship with Gender. 140
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 135
Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C. 135
Mild sialoadenitis: a common finding in patients with hepatitis C virus infection 133
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. 131
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients. 129
Splenic Artery Syndrome as a Possible Cause of Late Onset Refractory Ascites after Liver Transplantation: Management with Proximal Splenic Artery Embolization 129
Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass. 127
Consensus conference on TIPS management: Techniques, indications, contraindications 126
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 125
A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis 125
Specific issues concerning the management of patients on the waiting list and after liver transplantation 121
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. 120
Liver transplantation from old donors into HCV and non-HCV recipients 120
Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma. 118
Diagnostic usefulness of acute-phase protein measurement in hepatocellular carcinoma. 118
Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C 118
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy 118
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. 118
Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome. 117
Degree of bile-duct dilatation in liver-transplanted patients with biliary stricture: a magnetic resonance cholangiography-based study. 116
Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. 115
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 115
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C. 115
DIFFUSION-WEIGHTED MRI IN EVALUATING LIVER FIBROSIS: A FEASIBILITY STUDY IN CIRRHOTIC PATIENTS 114
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation 114
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 113
DE NOVO TUMORS ARE A MAJOR CAUSE OF LATE MORTALITY AFTER ORTHOTOPIC LIVER TRANSPLANTATION 113
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 113
Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients 113
Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome. 112
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. 112
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response. 112
Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment 112
Predictors of endoscopic treatment outcome in the management of biliary complications after orthotopic liver transplantation 111
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 111
Quality-of-life assessment before and after liver transplantation. 110
Safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients: A 5-year experience 110
Biliary strictures after liver transplantation: Role of interleukin 28B genotypes in cyclosporine treated 109
Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation 108
Acute alcoholic hepatitis and liver transplantation: Waiting for Godot 108
Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases 108
Clinical and virologic response to entecavir in HBV related chronic hepatitis or cirrhosis: data from the clinical practice in a single centre cohort. 107
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 107
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 107
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. 107
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. 105
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases 105
Weight gain after liver transplantation and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene 104
Vitamin D deficiency and HCV chronic infection: what comes first? 103
Impact of magnetic resonance cholangiography in managing liver-transplanted patients: preliminary results of a clinical decision-making study 103
Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end stage liver disease 103
Occult hepatitis B virus infection in peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. 103
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. 102
Prevalence and risk factors for delayed adrenal insufficiency after liver transplantation 101
Prevalence and impact on survival of occurrence of portal vein thrombosis in primary liver cancer 101
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 101
HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS 100
Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B 100
STEATOSIS OF THE HEPATIC GRAFT AS A RISK FACTOR FOR POST-TRANSPLANT BILIARY COMPLICATIONS 100
Favourable Outcome of Adefovir-Dipivoxil Treatment in Acute de Novo Hepatitis B After Liver Transplantation 100
Factors associated with serum HCV RNA positivity in anti HCV antibody positive intravenous drug users 99
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial 99
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 99
Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference 99
Antiviral treatment of hepatitis C 99
Low fibrosis progression of recurrent hepatitis C in apolipoprotein E e4 carriers: relationship with the blood lipid profile 99
IgM antibody response to the hepatitis C virus core protein in intravenous drug users. 98
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 97
Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications 97
GENE POLYMORPHISM AT THE INTERLEUKIN 6 -174 G > C LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 97
Relationship between vitamin D status and response to hepatitis C virus therapy 97
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients 97
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation 96
OCCULT HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C: RELATIONSHIP WITH DONOR AGE AND FIBROSIS PROGRESSION 96
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 96
Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. 95
Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C 95
Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. 95
Common issues in the management of patients in the waiting list and after liver transplantation 95
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 95
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 93
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. 93
Successful minimally invasive management of late portal vein thrombosis after splenectomy due to splenic artery steal syndrome following liver transplantation: a case report 93
Current challenges and future directions for liver transplantation 93
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 93
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. 92
Totale 11.442
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.154 306 215 190 841 399 801 603 577 422 367 121 312
2020/20212.986 86 314 218 364 110 419 174 290 370 110 362 169
2021/20221.861 81 149 112 110 27 104 108 97 32 278 479 284
2022/20232.254 259 167 35 304 229 580 1 174 339 25 79 62
2023/2024674 132 78 32 18 138 97 15 33 58 38 10 25
2024/202534 34 0 0 0 0 0 0 0 0 0 0 0
Totale 17.741